Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal sufentanil for analgesia of vaso-occlusive crisis in sickle-cell adults
2019-001274-29Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sufentanil in sickle cell disease (SCD) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of subjects relieved at 30 minutes. Started Jun 2019; status: completed.
02
Drugs
sufentanil
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-001274-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001274-29.